The US Food and Drug Administration (FDA) has approved a perioperative durvalumab (Imfinzi, AstraZeneca) regimen for adults with muscle-invasive bladder cancer. Specifically, the indication is for neoadjuvant durvalumab in combination with gemcitabine and cisplatin chemotherapy followed by adjuvant single agent durvalumab after radical cystectomy. Approval followed Priority Review and was based on efficacy demonstrated in […]
The post FDA Okays Perioperative Durvalumab for Bladder Cancer first appeared on News Health.
Author : News Health
Publish date : 2025-04-01 07:17:00
Copyright for syndicated content belongs to the linked Source.